Loader

Pathways

PathWhiz ID Pathway Meta Data

PW002098

Pw002098 View Pathway
metabolic

Sedoheptulose Bisphosphate Bypass

Escherichia coli
Sedoheptulose bisphospate bypass pathway demonstrates a series of reaction that form D-Erythrose 4-phosphate for pentose phosphate pathway and glycerone phosphate for glycolysis and pyruvate dehydrogenase pathway. D-Sedoheptulose 7-phosphate is obtained from pentose phosphate pathway, which later converted to sedoheptulose 1,7-bisphosphate via 6-phosphofructokinase-1. Fructose-bisphosphate aldolase class 2 catalyzes sedoheptulose 1,7-bisphosphate to form D-Erythrose 4-phosphate and pyruvate dehydrogenase.

PW000466

Pw000466 View Pathway
disease

Segawa Syndrome

Homo sapiens
Segawa syndrome is a condition in which the affected individual has a clumsy or unusual gait, and experiences involuntary muscle contractions and uncontrolled movements (dystonia). Some cases are mild, while others can be severe. The beginning signs of this condition are dystonia in the legs, and clubfeet. The cause of this condition is a mutation in the GCH1 gene. Tetrahydrobiopterin is an important compound in the production of neurotransmitters, specifically dopamine and serotonin, and the processing of quite a few amino acids, The mutation on GCH1 causes GTP cyclohydrase 1 production to be reduced or absent which causes the first three steps of tetrahydrobiopterin biosynthesis to be compromised. Dopamine is imperative in maintaining smooth muscle movements, which is why patients with Segawa syndrome experience movement problems and an unusual gait.

PW121811

Pw121811 View Pathway
disease

Segawa Syndrome

Mus musculus
Segawa syndrome is a condition in which the affected individual has a clumsy or unusual gait, and experiences involuntary muscle contractions and uncontrolled movements (dystonia). Some cases are mild, while others can be severe. The beginning signs of this condition are dystonia in the legs, and clubfeet. The cause of this condition is a mutation in the GCH1 gene. Tetrahydrobiopterin is an important compound in the production of neurotransmitters, specifically dopamine and serotonin, and the processing of quite a few amino acids, The mutation on GCH1 causes GTP cyclohydrase 1 production to be reduced or absent which causes the first three steps of tetrahydrobiopterin biosynthesis to be compromised. Dopamine is imperative in maintaining smooth muscle movements, which is why patients with Segawa syndrome experience movement problems and an unusual gait.

PW122036

Pw122036 View Pathway
disease

Segawa Syndrome

Rattus norvegicus
Segawa syndrome is a condition in which the affected individual has a clumsy or unusual gait, and experiences involuntary muscle contractions and uncontrolled movements (dystonia). Some cases are mild, while others can be severe. The beginning signs of this condition are dystonia in the legs, and clubfeet. The cause of this condition is a mutation in the GCH1 gene. Tetrahydrobiopterin is an important compound in the production of neurotransmitters, specifically dopamine and serotonin, and the processing of quite a few amino acids, The mutation on GCH1 causes GTP cyclohydrase 1 production to be reduced or absent which causes the first three steps of tetrahydrobiopterin biosynthesis to be compromised. Dopamine is imperative in maintaining smooth muscle movements, which is why patients with Segawa syndrome experience movement problems and an unusual gait.

PW127151

Pw127151 View Pathway
disease

Segawa Syndrome

Homo sapiens
Segawa syndrome is a condition in which the affected individual has a clumsy or unusual gait, and experiences involuntary muscle contractions and uncontrolled movements (dystonia). Some cases are mild, while others can be severe. The beginning signs of this condition are dystonia in the legs, and clubfeet. The cause of this condition is a mutation in the GCH1 gene. Tetrahydrobiopterin is an important compound in the production of neurotransmitters, specifically dopamine and serotonin, and the processing of quite a few amino acids, The mutation on GCH1 causes GTP cyclohydrase 1 production to be reduced or absent which causes the first three steps of tetrahydrobiopterin biosynthesis to be compromised. Dopamine is imperative in maintaining smooth muscle movements, which is why patients with Segawa syndrome experience movement problems and an unusual gait.

PW128142

Pw128142 View Pathway
drug action

Segesterone acetate Action Pathway

Homo sapiens
Segesterone acetate, also known as Annovera, is a synthetic progestin derived from 19-norprogesterone. This drug is very potent; it mediates progestational activity 100 times higher than that of progesterone. It is used as a contraceptive but also as a treatment for endometriosis in South American countries. Segesterone acetate binds selectively to progesterone receptors. This drug differs from other contraceptives because it needs to be administered parenterally since it is rapidly metabolized in the liver. Segesterone acetate is not active when taken orally, but it is proved to be an anti-ovulatory agent when given in implants, vaginal rings, or percutaneous gel. This drug acts by binding as an agonist to the progesterone receptors in the hypothalamus, this causes the level of production of Gonadotropin hormone-releasing hormone (GnRH) to increase. This lower the transcription of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) in the pituitary gland. This prevents ovulation by blocking the midcycle surge in LH, resulting in the inhibition of ovarian follicles. This drug is administered as a vaginal ring that is releasing the hormone for 21 days. The cycle of 21 days can be repeated for 13 cycles. This vaginal ring also contains ethinyl estradiol.

PW146856

Pw146856 View Pathway
drug action

Segesterone acetate Drug Metabolism Action Pathway

Homo sapiens

PW128323

Pw128323 View Pathway
drug action

Selegiline Action Pathway

Homo sapiens
Selegiline is an irreversible monoamine oxidase inhibitor (MAOIs). It is indicated for the initial treatment of Parkinson's disease and for adjunct therapy in patients that are having decreased response to levodopa or carbadopa. This molecule can also be used as a palliative treatment of Alzheimer's disease and at very high doses, for the treatment of depression. The monoamine oxidase is an enzyme that catalyzes the oxidative deamination of many amines like serotonin, norepinephrine, epinephrine, and dopamine. There are 2 isoforms of this protein: A and B. The first one is found in cells located in the periphery and breakdown serotonin, norepinephrine, epinephrine, dopamine, and tyramine. The second one, the B isoform, breakdowns phenylethylamine, norepinephrine, epinephrine, dopamine, and tyramine. This isoform is found in the extracellular tissues and mostly in the brain. The mechanism of action of the MAOIs is still not determined, it is thought that they act by increasing free serotonin and norepinephrine concentrations and/or by altering the concentrations of other amines in the CNS. MAO-A inhibition is thought to be more relevant to antidepressant activity than the inhibition caused by MAO B. Selective MAO B inhibitors have no antidepressant effects. MAO-B is involved in the nigrostriatal pathways, it accelerates the breakdown of dopamine in the cells. Selegiline binds selectively to MAO-B, this hinders the microsomal breakdown of dopamine, thereby amplifying the dopaminergic activities in the substantial nigra. At higher doses, selegiline can also binds MAO-A, enabling its application in depression treatment. This drug is administered as an oral tablet.

PW145133

Pw145133 View Pathway
drug action

Selegiline Drug Metabolism Action Pathway

Homo sapiens

PW146212

Pw146212 View Pathway
drug action

Selenic acid Drug Metabolism Action Pathway

Homo sapiens